An Open-Label, Multicenter Study Investigating RP3 Oncolytic Immunotherapy in Combination with First- or Second-Line Systemic Atezolizumab Plus Bevacizumab in Patients with Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
JOURNAL OF CLINICAL ONCOLOGY（2024）
Key words
283-424-425,281-318-430,3282-270-9760,261-566-11347,298-145-222-184-4809-5347,281-318-430,3282-3306-2822,613-135-244-3829-325,182,1854,3604,3604,38092-26716
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined